Insider · CIK 0001238401

LANGE LOUIS G

Reports to the SEC for 9 companies · NAARDEN, P7

sec.gov

Transactions

Companies

Filings

CIK

0001238401

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-11	NAMSNewAmsterdam Pharma Co N.V.S Sale	Director	SSale	−44.2K sh	$30.41	−$1.34M	10,806
2026-03-11	NAMSNewAmsterdam Pharma Co N.V.S Sale	Director	SSale	−446 sh	$31.23	−$13.9K	10,360
2026-03-09	NAMSNewAmsterdam Pharma Co N.V. · Warrant (right to buy)X Exercise of In-Money	Director	XExercise of In-Money	−44.6K sh	—	—	0
2026-03-09	NAMSNewAmsterdam Pharma Co N.V.X Exercise of In-Money	Director	XExercise of In-Money	+44.6K sh	$11.50	+$513K	54,979
2026-03-06	NAMSNewAmsterdam Pharma Co N.V.S Sale	Director	SSale	−28.2K sh	$29.41	−$829K	0
2026-01-07	NAMSNewAmsterdam Pharma Co N.V.A Award	Director	AAward	+3,400 sh	—	—	10,360
2026-01-07	NAMSNewAmsterdam Pharma Co N.V. · Option (right to buy)A Award	Director	AAward	+15.3K sh	—	—	15,300
2025-06-01	NAMSNewAmsterdam Pharma Co N.V.M Exercise/Conversion	Director	MExercise/Conversion	+68 sh	—	—	28,186
2025-06-01	NAMSNewAmsterdam Pharma Co N.V. · Restricted Stock UnitM Exercise/Conversion	Director	MExercise/Conversion	−68 sh	—	—	0
2025-05-01	NAMSNewAmsterdam Pharma Co N.V. · Restricted Stock UnitM Exercise/Conversion	Director	MExercise/Conversion	−69 sh	—	—	68
2025-05-01	NAMSNewAmsterdam Pharma Co N.V.M Exercise/Conversion	Director	MExercise/Conversion	+69 sh	—	—	28,118
2025-04-14	NAMSNewAmsterdam Pharma Co N.V.M Exercise/Conversion	Director	MExercise/Conversion	+69 sh	—	—	28,049
2025-04-14	NAMSNewAmsterdam Pharma Co N.V. · Restricted Stock UnitM Exercise/Conversion	Director	MExercise/Conversion	−69 sh	—	—	137
2025-03-26	NAMSNewAmsterdam Pharma Co N.V. · Restricted Stock UnitA Award	Director	AAward	+3,308 sh	—	—	3,308
2025-03-26	NAMSNewAmsterdam Pharma Co N.V. · Restricted Stock UnitM Exercise/Conversion	Director	MExercise/Conversion	−3,102 sh	—	—	206
2025-03-26	NAMSNewAmsterdam Pharma Co N.V.M Exercise/Conversion	Director	MExercise/Conversion	+3,102 sh	—	—	10,062
2025-01-07	NAMSNewAmsterdam Pharma Co N.V.A Award	Director	AAward	+6,960 sh	—	—	6,960
2025-01-06	NAMSNewAmsterdam Pharma Co N.V. · Option (right to buy)A Award	Director	AAward	+32.5K sh	—	—	32,500
2024-02-13	NAMSNewAmsterdam Pharma Co N.V.P Purchase	Director	PPurchase	+5,000 sh	$19.00	+$95K	24,878
2024-01-01	NAMSNewAmsterdam Pharma Co N.V. · Option (right to buy)A Award	Director	AAward	+10K sh	—	—	10,000
2020-01-15	Audentes Therapeutics, Inc.U Disposition from Tender	Director	UDisposition from Tender	−13.7K sh	$60.00	−$821K	0
2020-01-15	Audentes Therapeutics, Inc.U Disposition from Tender	Director	UDisposition from Tender	−266K sh	$60.00	−$15.9M	0
2020-01-15	Audentes Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−9,000 sh	—	—	0
2020-01-15	Audentes Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−16.2K sh	—	—	0
2020-01-15	Audentes Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10K sh	—	—	0
2020-01-15	Audentes Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−18K sh	—	—	0
2020-01-15	Audentes Therapeutics, Inc.U Disposition from Tender	Director	UDisposition from Tender	−3,555 sh	$60.00	−$213K	0
2020-01-15	Audentes Therapeutics, Inc.U Disposition from Tender	Director	UDisposition from Tender	−32.3K sh	$60.00	−$1.94M	0
2019-12-23	Audentes Therapeutics, Inc.S Sale	Director	SSale	−1,000 sh	$59.60	−$59.6K	13,678
2019-12-23	Audentes Therapeutics, Inc.S Sale	Director	SSale	−10K sh	$59.60	−$596K	265,799
2019-09-23	Audentes Therapeutics, Inc.S Sale	Director	SSale	−245 sh	$32.66	−$8,002.386	275,799
2019-09-23	Audentes Therapeutics, Inc.S Sale	Director	SSale	−9,755 sh	$32.15	−$314K	276,044
2019-09-23	Audentes Therapeutics, Inc.S Sale	Director	SSale	−1,000 sh	$32.18	−$32.2K	14,678
2019-06-24	Audentes Therapeutics, Inc.S Sale	Director	SSale	−15.8K sh	$37.60	−$594K	290,001
2019-06-24	Audentes Therapeutics, Inc.S Sale	Director	SSale	−200 sh	$39.46	−$7,892	15,678
2019-06-24	Audentes Therapeutics, Inc.S Sale	Director	SSale	−800 sh	$37.89	−$30.3K	15,878
2019-06-24	Audentes Therapeutics, Inc.S Sale	Director	SSale	−3,602 sh	$38.15	−$137K	286,399
2019-06-24	Audentes Therapeutics, Inc.S Sale	Director	SSale	−600 sh	$40.00	−$24K	285,799
2019-03-25	Audentes Therapeutics, Inc.S Sale	Director	SSale	−558 sh	$35.94	−$20.1K	0
2019-03-25	Audentes Therapeutics, Inc.S Sale	Director	SSale	−19.7K sh	$35.99	−$709K	306,099
2019-03-25	Audentes Therapeutics, Inc.S Sale	Director	SSale	−300 sh	$36.64	−$11K	305,799
2019-03-25	Audentes Therapeutics, Inc.S Sale	Director	SSale	−1,000 sh	$36.00	−$36K	16,678
2019-02-06	Audentes Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+16.2K sh	—	—	16,200
2018-12-24	Audentes Therapeutics, Inc.S Sale	Director	SSale	−10K sh	$18.50	−$185K	32,343
2018-12-24	Audentes Therapeutics, Inc.S Sale	Director	SSale	−1,000 sh	$18.71	−$18.7K	558
2018-12-24	Audentes Therapeutics, Inc.S Sale	Director	SSale	−1,000 sh	$18.70	−$18.7K	17,678
2018-12-24	Audentes Therapeutics, Inc.S Sale	Director	SSale	−20K sh	$18.67	−$373K	325,799
2018-11-15	Audentes Therapeutics, Inc.S Sale	Director	SSale	−4,000 sh	$22.49	−$90K	3,555
2018-11-15	Audentes Therapeutics, Inc.S Sale	Director	SSale	−20K sh	$22.49	−$450K	345,799
2018-09-24	Audentes Therapeutics, Inc.S Sale	Director	SSale	−1,000 sh	$37.27	−$37.3K	18,678

Recent filings

Accepted (ET)
Mar 124
LANGE LOUIS G0001193125-26-104239
SEC(opens sec.gov)
Mar 104
LANGE LOUIS G0001193125-26-100798
SEC(opens sec.gov)
Jan 94
LANGE LOUIS G0001193125-26-009268
SEC(opens sec.gov)
Jun 34
LANGE LOUIS G0000950170-25-081072
SEC(opens sec.gov)
May 24
LANGE LOUIS G0000950170-25-062894
SEC(opens sec.gov)
Apr 214
LANGE LOUIS G0000950170-25-056395
SEC(opens sec.gov)
Mar 284
LANGE LOUIS G0000950170-25-046958
SEC(opens sec.gov)
Jan 84
LANGE LOUIS G0000950170-25-003552
SEC(opens sec.gov)
Feb 214
LANGE LOUIS G0000950170-24-018045
SEC(opens sec.gov)
Jan 34
LANGE LOUIS G0000950170-24-001128
SEC(opens sec.gov)

Companies

Address

C/O NEWAMSTERDAM PHARMA COMPANY N.V. GOOIMEER 2-35

NAARDEN, P7, 1411 DC